Top Boston, MA Biotech Companies (301)
Click Therapeutics, Inc., develops, validates, and commercializes software as prescription medical treatments for people with unmet medical needs. As a leading innovator of Digital Therapeutics™, Click delivers accessible, clinically proven, FDA-regulated prescription treatments to the smartphone in your hand. Click’s treatments are defined by a commitment to applying technical and scientific rigor and patient-centric design to the development process. This...
Biotechnology is rewriting life as we know it, from the medicines we take, to the crops we grow, and the household goods that we rely on every day. But moving at the new speed of science requires better technology. Benchling’s mission is to unlock the power of biotechnology. The world’s most innovative biotech companies use Benchling’s R&D Cloud to power the...
SOPHiA GENETICS (Nasdaq: SOPH) is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform...
We bring together one of the world’s largest libraries of multimodal clinical and molecular data with a robust suite of AI tools to help physicians personalize care in real time, connect patients with therapies and clinical trials, and enable partners to accelerate discovery and development of new treatments. With ~8 million de-identified research records and 350+ petabytes of data, Tempus partners...
Schrödinger is a leading provider of advanced molecular simulations and enterprise software solutions and services for pharmaceutical, biotechnology, and materials science research. The predictive power of Schrödinger's software allows scientists to accelerate their research and development, reduce research costs, and make novel discoveries.
Mediar Therapeutics is pioneering a new approach to fibrosis treatment that aims to halt the disease at a different source – the myofibroblast, the key pathogenic cell in fibrosis that drives scarring, disease progression, and ultimately organ failure. Mediar was founded based on a deep understanding of the complex science underlying fibrosis progression. By combining novel targets with reliable, easily detectable...
Photys Therapeutics’ proprietary bifunctional small molecules platform unlocks fine-tuned control of protein post-translational modifications, going beyond degradation to restore protein function, repair signaling, and amplify endogenous disease-fighting mechanisms. Photys was co-founded by the Broad Institute’s leading bifunctional chemist, Amit Choudhary, and the Longwood Fund, alongside a scientific advisory board comprised of distinguished scientists and drug developers – MIT’s Angela Koehler,...
PIC Therapeutics is a biotechnology company focused on fundamentally changing how we treat cancer by developing a new generation of therapeutics based on the modulation of RNA translation. PIC Therapeutics was founded on the seminal work of Dr. Gerhard Wagner, a professor at Harvard Medical School world-renowned for his scientific expertise in protein structure and his research on interactions of...
The Future of Glyco-therapeutics Aviceda Therapeutics is a disruptive clinical-stage biotech company focused on the next generation of immuno-modulators by harnessing the power of glycobiology to address the innate immune system and chronic non-resolving inflammation specifically and profoundly using a propriety HALOS platform Technology. Aviceda is developing glyco-immuno therapeutics targeting devastating ocular and systemic degenerative, fibrotic, and immuno-inflammatory diseases. A combination of cutting-edge...
The Bill & Melinda Gates Medical Research Institute is a non-profit organization dedicated to the development and effective use of novel biomedical interventions addressing substantial global health concerns, for which investment incentives are limited. The institute works through collaborating partners and organizations, coordinating and driving the full spectrum of biopharmaceutical development activities, including pre-clinical development, full clinical development (from phase...
Verve Therapeutics is a clinical-stage biotechnology company created with a singular focus: to protect the world from heart disease. Founded by world-leading experts in cardiovascular medicine, human genetics and gene editing, the company aims to develop transformative, once-and-done therapies for coronary heart disease. Verve’s gene editing medicines are designed to safely edit the genome of adults and mimic naturally occurring...
Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.
We are a biotechnology company pioneering new treatment options for neurodegenerative diseases by utilizing our proprietary RNA interference platform. We were founded by Anastasia Khvorova, Ph.D., Craig Mello, Ph.D., and Neil Aronin, M.D., of the RNA Therapeutics Institute at the University of Massachusetts Medical School, with a Series A funding exclusively by F-Prime Capital. We are headquartered in Boston, Mass.
Flagship Pioneering conceives, creates, resources, and develops first-in-category life sciences companies to transform human health and sustainability. Since its launch in 2000, the firm has applied a unique, hypothesis-driven innovation process to originate and foster more than 100 scientific ventures, resulting in over $30 billion in aggregate value. To date, Flagship is backed by >$3 billion of aggregate capital commitments,...
At Ginkgo, we use biology to grow the future. Companies across industries leverage our platform to design, develop, and optimize products for a breadth of commercial applications. We help our partners grow key ingredients for vaccines, crops that rely less on fossil fuel-based fertilizers, plant-based meat that tastes like the real thing, materials for the next generation of circular fashion,...
From discovery to product launch and lifecycle management At VCLS (Voisin Consulting Life Sciences), regulatory science guides Biotechnology, Pharmaceutical and Medtech manufacturers throughout product development and commercialization. Starting early in the process, from discovery to the patient, VCLS assists innovators in designing optimized product development plans and regulatory strategies, combining the health ecosystem with commercial success. With a presence in seven...
Orbital Therapeutics aims to enhance global health by unleashing the full potential of RNA-based medicines (excluding RNAi therapeutics) to treat human disease in ways that were not previously possible. We’re building a first-in-kind platform designed to sit at the intersection of RNA technology delivery methods, data science and automation to develop an expansive portfolio of medicines, initially focused in the...
argenx is a global immunology company committed to improving the lives of people living with severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx is translating immunology breakthroughs into a world-class portfolio of novel antibody-based medicines.
nference is making the world's biomedical knowledge computable to solve urgent healthcare problems. The company was co-founded by Venky Soundararajan, Ph.D. and Murali Aravamudan.
Work Your Passion. Live Your Purpose.
